March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's combination treatment ...

Now, the person making the call is somebody somewhere who works for (the insurance company). It’s not my physician, who’s an ...

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...

SNV4818 is an oral treatment being evaluated in an early and mid-stage study for breast cancer and other advanced solid ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

According to a spokesperson for Neal Dunn the FAIC Act aims to guarantee that Medicare cancer patients have access to the ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...

Scientists have mapped the genetics of cancer in cats for the first time at scale, uncovering major overlaps with human ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to bolster its oncology pipeline.

FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

The very first patient would receive the first clinical doses of HMBD-001, the first cancer treatment from Hummingbird Bioscience. Piers Ingram, the cofounder and CEO of the company, was nervous, but ...